Details

Autor(en) / Beteiligte

• Zambrano, Laura D
• Newhams, Margaret M
• Olson, Samantha M
• Halasa, Natasha B
• Price, Ashley M
• Orzel, Amber O
• Young, Cameron C
• Boom, Julie A
• Sahni, Leila C
• Maddux, Aline B
• Bline, Katherine E
• Kamidani, Satoshi
• Tarquinio, Keiko M
• Chiotos, Kathleen
• Schuster, Jennifer E
• Cullimore, Melissa L
• Heidemann, Sabrina M
• Hobbs, Charlotte V
• Nofziger, Ryan A
• Pannaraj, Pia S
• Cameron, Melissa A
• Walker, Tracie C
• Schwartz, Stephanie P
• Michelson, Kelly N
• Coates, Bria M
• Flori, Heidi R
• Mack, Elizabeth H
• Smallcomb, Laura
• Gertz, Shira J
• Bhumbra, Samina S
• Bradford, Tamara T
• Levy, Emily R
• Kong, Michele
• Irby, Katherine
• Cvijanovich, Natalie Z
• Zinter, Matt S
• Bowens, Cindy
• Crandall, Hillary
• Hume, Janet R
• Patel, Manish M
• Campbell, Angela P
• Randolph, Adrienne G

Titel

BNT162b2 mRNA Vaccination Against Coronavirus Disease 2019 is Associated With a Decreased Likelihood of Multisystem Inflammatory Syndrome in Children Aged 5-18 Years-United States, July 2021 - April 2022

Ist Teil von

• Clinical infectious diseases, 2023-02, Vol.76 (3), p.e90-e100

Ort / Verlag

United States

Erscheinungsjahr

2023

Quelle

Oxford Journals 2020 Medicine

Beschreibungen/Notizen

• Multisystem inflammatory syndrome in children (MIS-C), linked to antecedent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, is associated with considerable morbidity. Prevention of SARS-CoV-2 infection or coronavirus disease 2019 (COVID-19) by vaccination might also decrease MIS-C likelihood. In a multicenter, case-control, public health investigation of children ages 5-18 years hospitalized from 1 July 2021 to 7 April 2022, we compared the odds of being fully vaccinated (2 doses of BNT162b2 vaccine ≥28 days before hospital admission) between MIS-C case-patients and hospital-based controls who tested negative for SARS-CoV-2. These associations were examined by age group, timing of vaccination, and periods of Delta and Omicron variant predominance using multivariable logistic regression. We compared 304 MIS-C case-patients (280 [92%] unvaccinated) with 502 controls (346 [69%] unvaccinated). MIS-C was associated with decreased likelihood of vaccination (adjusted OR [aOR]: .16; 95% CI: .10-.26), including among children ages 5-11 years (aOR: .22; 95% CI: .10-.52), ages 12-18 years (aOR: .10; 95% CI: .05-.19), and during the Delta (aOR: .06; 95% CI: .02-.15) and Omicron (aOR: .22; 95% CI: .11-.42) variant-predominant periods. This association persisted beyond 120 days after the second dose (aOR: .08; 95% CI: .03-.22) in 12-18-year-olds. Among all MIS-C case-patients, 187 (62%) required intensive care unit admission and 280 (92%) vaccine-eligible case-patients were unvaccinated. Vaccination with 2 doses of BNT162b2 is associated with reduced likelihood of MIS-C in children ages 5-18 years. Most vaccine-eligible hospitalized patients with MIS-C were unvaccinated.